SHR-2017

N/A

Report date: 2025/06/13 20:00:59
First In Class

Base Information

Drug NameSHR-2017
Drug Alias NameSHR-2017SHR2017
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of Actionanti-Tumor necrosis factor ligand superfamily member 11Anti-Nerve growth factor
TargetsTumor necrosis factor ligand superfamily member 11Nerve growth factor
Therapy Area/IndicationsBone metastasesSolid tumoursOsteoporosis +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesSuzhou Suncadia Biopharmaceuticals Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesSuzhou Suncadia Biopharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsBone metastasesSolid tumoursOsteoporosis +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A